Holland & Knight Leads Kos Pharmaceuticals, Inc. Buyout by Abbott Laboratories for $3.7 Billion
07 Novembre 2006 - 5:21PM
PR Newswire (US)
NEW YORK, Nov. 7 /PRNewswire/ -- Holland & Knight LLP announces
the representation, along with Cravath, Swaine and Moore, of its
client Kos Pharmaceuticals, Inc. (NASDAQ:KOSP) in the sale of Kos
to global health care products maker Abbott (NYSE:ABT) for
approximately $3.7 billion net of cash currently held by Kos. The
Holland & Knight team was led by Miami-based partner Steven
Sonberg and Tampa-based partner Robert Grammig and partner Richard
Yanofsky. The team from Cravath was led by partners Alan
Stephenson, Sarkis Jebejian and Eric Hilfers. Based in Cranbury,
N.J., Kos Pharmaceuticals, Inc. ("Kos" or the "Company") -- named
after the Greek island where Hippocrates founded the science of
medicine -- is a fully integrated specialty pharmaceutical company
engaged in the development of proprietary prescription
pharmaceutical products, principally for treatment of
cardiovascular, respiratory and metabolic diseases. The Company's
principal product development strategy is to reformulate existing
pharmaceutical products with large market potential to improve
safety, effectiveness and patient compliance. Under the terms of
the agreement, Abbott will make a tender offer for all of the
outstanding stock of Kos for $78 per share. Holland & Knight
has represented Kos in two public offerings and a number of
acquisitions for approximately 10 years. About Holland & Knight
LLP: Holland & Knight is a global law firm with more than 1,150
lawyers in 17 U.S. offices. Other offices around the world are
located in Mexico City, Tokyo and Beijing, with representative
offices in Caracas, Helsinki and Tel Aviv. Holland & Knight is
among the world's 15 largest firms, providing representation in
litigation, business, real estate and governmental law. Our
interdisciplinary practice groups and industry-based teams ensure
clients have access to attorneys with the best expertise,
regardless of location. http://www.hklaw.com/ DATASOURCE: Holland
& Knight LLP CONTACT: Christina Calhoun of Holland & Knight
+1-813-769-4355, Web site: http://www.hklaw.com/
Copyright
Grafico Azioni Kos (NASDAQ:KOSP)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Kos (NASDAQ:KOSP)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Kos Pharmaceuticals (NASDAQ): 0 articoli recenti
Più Kos Pharmaceuticals (MM) Articoli Notizie